Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UF oncologists fight leukemia with two-pronged therapy, clinical trials planned

04.06.2010
A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

Like striking an enemy camp directly as well as cutting off its source of food and other resources, the agent, called Oxi4503, poisons leukemia cells and destroys the blood vessels that supply them with oxygen and nutrients.

Use of the treatment in mouse models of acute myelogenous leukemia, or AML, is described online and in an upcoming print issue of the journal Blood. The researchers plan human tests of the drug at Shands at UF later this year.

"We've identified a new tool to dissect out the specifics of the relationship between leukemia cells and the blood vessels that supply them," said Christopher Cogle, M.D., the UF College of Medicine oncologist who is senior author of the paper and a member of the UF Shands Cancer Center. "What we are offering is a brand new treatment by a very different mechanism to people who desperately need something new."

Each year, more than 120,000 people in the United States are diagnosed with a blood cancer, and about 80 percent of them die of the disease because there are no effective treatments, according to the National Cancer Institute. Some AMLs return after initially successful chemotherapy, while others do not respond at all. In addition, chemotherapy is too toxic for some elderly people, so they need an alternative.

Many treatments and studies focus on killing cancer cells, but very few target the microenvironment in which those cells grow. That means paying attention to blood vessels, bone marrow, growth factors and cell-to-cell interaction and binding.

Existing therapies that destroy blood vessels do so by targeting a growth factor called VEGF-A, but they are not effective long term at eliminating leukemia. To try to find a strategy that attacked multiple targets, the researchers tested Oxi4503, a novel blood vessel-disrupting agent.

In mouse models, Oxi4503 killed leukemia cells in addition to destroying the blood vessels that fed and nurtured them.

"It is very exciting to find one drug that can target both the leukemic cell and the endothelium to diminish the progression of leukemias — those people who fail chemotherapy, early or late, could be treated with this drug to see whether they respond," said Shahin Rafii, M.D., a Howard Hughes Medical Institute Investigator and director of the Ansary Stem Cell Institute at Weill Cornell Medical College, who showed that leukemia cells are dependent on activated bone marrow blood vessels for survival and proliferation. Rafii is not affiliated with the UF study.

After Oxi4503 treatment, however, the researchers found that a thin layer of viable tumor tissue remained that was fed by newly formed vessels. The cells supplied by those vessels showed increased expression of a growth factor, as is often found in oxygen-deficient areas.

To disrupt this secondary formation of blood vessels, the researchers blocked the growth factor VEGF by administering an antibody called bevacizumab after the blood vessel-destroying agent OXi4503. The combined approach led to enhanced leukemia regression.

The research, funded by the National Institutes of Health and the Leukemia and Lymphoma Society, has implications for both basic science and clinical research, as the results suggest that potential therapies must be screened against not only leukemia cells, but also the environment with which they interact.

"It's a major paradigm shift," Rafii said.

Describing the studies as "elegant," Judith Karp, M.D., a professor of oncology and medicine and director of the leukemia program of the Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University, said the findings support the notion that VEGF and the vascular milieu are extremely important in cancer cell survival, and that targeting them might be a good anti-cancer strategy. Karp pioneered the use of bevacizumab — the antibody used in the UF studies — after chemotherapy, which resulted in remission among patients with cancer that was resistant to chemotherapy or that had returned after treatment.

"The results are extremely exciting and need to be implemented clinically in a very prioritized and timely fashion," said Karp, who was not affiliated with the study.

Indeed, the U.S. Food and Drug Administration quickly gave its approval in April for a phase 1 clinical trial. That means the treatment could be available by late 2010 or the start of 2011 to eligible study volunteers at Shands at UF, as soon as the researchers are able to obtain the necessary funding for the trial.

The initial two-year trial is not designed to determine whether the drug works, but rather to determine the maximum tolerable dose. It will involve three dozen individuals age 18 and older whose cancer is growing despite previous treatment. Trial details are at the National Institutes of Health website http://clinicaltrials.gov. Search for "NCT01085656."

Czerne M. Reid | EurekAlert!
Further information:
http://www.ufl.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>